bioRxiv / medRxiv
open access
CC BY-NC-ND 4.0
Genotype-guided isoniazid dosing harmonizes drug exposure in 3HP tuberculosis preventive therapy
RationalePolymorphisms in the N-acetyltransferase 2 (NAT2) gene explain much of the interindividual variation in isoniazid (INH) metabolism and determine risk of toxicities. However, there is limited evidence to guide INH dose adjustment according to the NAT2 acetylator profile in weekly rifapentine
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Isoniazid Dosage Prediction Model Development#870774
- TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment#839951
- Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)#160411
- TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection#969978
- Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis#1095481
Record · ID 1136721
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive